Alliancebernstein L.P. boosted its stake in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 49.3% during the first quarter, Holdings Channel reports. The institutional investor owned 39,664 shares of the specialty pharmaceutical company’s stock after buying an additional 13,092 shares during the period. Alliancebernstein L.P.’s holdings in Valeant Pharmaceuticals International were worth $437,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in VRX. KBC Group NV bought a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $5,031,000. Dimensional Fund Advisors LP raised its position in shares of Valeant Pharmaceuticals International by 86.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 576,634 shares of the specialty pharmaceutical company’s stock worth $8,372,000 after buying an additional 268,116 shares in the last quarter. ING Groep NV bought a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $2,850,000. Jones Collombin Investment Counsel Inc raised its position in shares of Valeant Pharmaceuticals International by 1,415.1% in the first quarter. Jones Collombin Investment Counsel Inc now owns 249,765 shares of the specialty pharmaceutical company’s stock worth $2,755,000 after buying an additional 233,280 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $2,529,000. Institutional investors and hedge funds own 51.14% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (VRX) traded up 0.65% during mid-day trading on Friday, hitting $13.90. 1,612,327 shares of the stock were exchanged. The firm has a 50-day moving average price of $16.61 and a 200-day moving average price of $13.38. The stock’s market capitalization is $4.84 billion. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same period in the prior year, the company earned ($0.88) EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 7.7% on a year-over-year basis. Equities analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alliancebernstein L.P. Purchases 13,092 Shares of Valeant Pharmaceuticals International, Inc. (VRX)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.watchlistnews.com/alliancebernstein-l-p-purchases-13092-shares-of-valeant-pharmaceuticals-international-inc-vrx/1475072.html.

A number of brokerages recently issued reports on VRX. Jefferies Group LLC set a $18.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Saturday, May 6th. Piper Jaffray Companies set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “sell” rating in a research report on Wednesday. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Wednesday. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Thursday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $17.31.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.